关于经典名方研发中处方制剂要求的困惑与建议  

Confusion and Suggestions on Prescription Conditions in Research and Development of TCM Classical Prescription

作　　者：梅雨 陈仁寿 施铮 李陆杰 MEI Yu;CHEN Ren-shou;SHI Zheng;LI Lu-jie(Institute of TCM Literature,Nanjing University of Chinese Medicine,Nanjing,210023,China)

机构地区：[1]南京中医药大学中医药文献研究所

出　　处：《南京中医药大学学报》2019年第4期373-375,共3页Journal of Nanjing University of Traditional Chinese Medicine

基　　金：国家科技部“十一五”科技支撑计划(2007bai10b07);国家自然科学基金(81574099)

摘　　要：《古代经典名方中药复方制剂简化注册审批管理规定》第三条关于处方制剂7个条件均存在不合理或操作困难的问题,给研发工作带来诸多困惑,建议尽早进行修订,以符合经典名方本身的规律、内涵与需求。The seven conditions for prescription preparation on Administrative Regulations of Simplifying Registration and Approval of Ancient TCM Classical Prescriptions of Traditional Chinese Medicine Compound Preparations are unreasonable or difficult to operate,which brings a lot of confusion to the research and development work. It is suggested to revise it as soon as possible, in order to conform to the laws,connotation and needs of TCM classical prescriptions.

关 键 词：经典名方 管理规定 建议 

分 类 号：R283[医药卫生—中药学]